Abstract
Diabetes mellitus (DM) is an established, independent risk factor for colorectal cancer (CRC). Metformin is the first drug of choice for type 2 DM. Several studies have shown a decreased risk of developing CRC in patients with metformin-treated DM, compared with patients with diabetes not treated with metformin. An increased overall survival and CRC-specific survival in patients with CRC and metformin-treated DM has still not been substantially proven. Further studies are needed before a conclusion can be made whether metformin should be used in the treatment of CRC.
| Bidragets oversatte titel | Metformin can reduce the risk of colorectal cancer |
|---|---|
| Originalsprog | Dansk |
| Sider (fra-til) | V12140659 |
| Tidsskrift | Ugeskrift for laeger |
| Vol/bind | 177 |
| Udgave nummer | 21 |
| Status | Udgivet - 18 maj 2015 |